We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GROMW
176
DELISTED
Grom Social Enterprises Inc. Warrants
GROMW
$32K ﹤0.01%
982
– –
FEED
177
ENvue Medical Inc
FEED
$2.09M
$21K ﹤0.01%
+5
New +$22.2K
TRX icon
178
PUT
TRX Gold Corp
TRX
$259M
$20K ﹤0.01%
404
-1,164
-74% -$527
ITP icon
179
PUT
IT Tech Packaging
ITP
$2.92M
$17K ﹤0.01%
25
-98
-80% -$411
TRX icon
180
TRX Gold Corp
TRX
$259M
$6K ﹤0.01%
+12,213
New +$5.53K
ATER icon
181
Aterian
ATER
$4.21M
– –
-36,083
Closed -$4M
ATOS icon
182
Atossa Therapeutics
ATOS
$24.1M
– –
-69,732
Closed -$4.06M
BCTX
183
Briacell Therapeutics
BCTX
$30.2M
– –
-1,307
Closed -$1.04M
BIIB icon
184
Biogen
BIIB
$30.4B
– –
-4,000
Closed -$1.39M
BTCT icon
185
BTC Digital
BTCT
$8.46M
– –
-1,223
Closed -$712K
CLRB icon
186
Cellectar Biosciences
CLRB
$20M
– –
-1,422
Closed -$508K
CVM icon
187
CEL-SCI Corp
CVM
$21M
– –
-4,843
Closed -$1.26M
HEPA
188
CALL
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-1
Closed -$220K
HEPA
189
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-1
Closed -$194K
JOB icon
190
GEE Group
JOB
$23.1M
– –
-700,000
Closed -$401K
NMAD
191
Nomad Power Solutions
NMAD
$81M
– –
-6,551
Closed -$199K
LIXTW
192
DELISTED
Lixte Biotechnology Warrants
LIXTW
– –
-140,089
Closed -$107K
MGNX icon
193
CALL
MacroGenics
MGNX
$245M
– –
-92
Closed -$247K
MGNX icon
194
PUT
MacroGenics
MGNX
$245M
– –
-182
Closed -$489K
PPBT
195
Purple Biotech
PPBT
$1.28M
– –
-253
Closed -$245K
RDHL
196
CALL
Redhill Biopharma
RDHL
$4.44M
– –
0
– -$117K
RDHL
197
Redhill Biopharma
RDHL
$4.44M
– –
-340
Closed -$2.34M
SHIP icon
198
Seanergy Maritime Holdings
SHIP
$348M
– –
-65,000
Closed -$728K
DCOY
199
Decoy Therapeutics
DCOY
$2.15M
– –
-7
Closed -$264K
TVTX icon
200
Travere Therapeutics
TVTX
$5.2B
– –
-10,042
Closed -$147K
5 6 7
8
9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.